GRI Bio ( NASDAQ: GRI ) has received notice on July 2, 2024, from The Nasdaq that the Co. regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq . “We are very excited about this development and look forward to focusing our efforts on our core business-developing novel product candidates for the treatment of inflammatory, fibrotic and autoimmune diseases,” said Marc Hertz, GRI Bio’s CEO.
More on GRI Bio GRI Bio announces pricing of $4 million public offering Financial information for GRI Bio.
